Semaglutide and erectile dysfunction: what does the evidence say?

Does semaglutide actually cause erectile dysfunction?

This question comes up often, and it deserves a clear answer rather than hedging. ED does not appear in the recognised side-effect profile for semaglutide. The NHS semaglutide page lists the common and serious side effects of the medicine (the list is led by gastrointestinal symptoms) and erectile dysfunction is not among them. The same is true of the prescribing information held on the Electronic Medicines Compendium, which contains the full Summary of Product Characteristics for Wegovy.

That does not mean every man's experience will be identical. A small number of people report low libido or sexual side effects early in treatment, but these are typically tied to the broader physical adjustment (nausea, reduced appetite, and fatigue) rather than any direct effect on sexual physiology. When those early symptoms settle, which they usually do within the first few weeks, most men find no lasting impact on sexual function.

If you'd like a fuller picture of how semaglutide works and what the treatment involves more broadly, that page covers the medicine in detail, including how semaglutide 3mg fits into the titration schedule and what to expect at that stage of dosing.

Could weight loss from semaglutide actually help with ED?

There is a reasonable biological case that it might. Obesity is one of the better-documented modifiable risk factors for erectile dysfunction. The mechanism runs in several directions: excess weight raises cardiovascular risk, impairs blood vessel function, and is associated with lower testosterone and higher oestrogen levels in men. Improving all of those markers (which meaningful weight loss tends to do) creates conditions in which sexual function can improve.

The STEP 1 trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks with semaglutide 2.4mg alongside lifestyle changes. That degree of weight loss, sustained, is the kind that measurably shifts cardiovascular and metabolic markers. Some subsequent research has looked specifically at sexual function in men losing weight on GLP-1 medicines and found improvements, though this area is still being studied and the evidence is not yet definitive enough to make confident individual predictions.

Put simply: semaglutide is not a treatment for ED, but if obesity is part of what is driving a man's ED, then treating the obesity is clinically sensible on its own terms. Sexual health may follow. A prescriber can talk through what that might mean in your specific situation.

What should you do if you notice changes in sexual function on semaglutide?

First: do not stop the medicine on your own without speaking to your prescriber. If you are experiencing ED or a change in sexual function that began around the time you started semaglutide or increased a dose, it is worth checking whether something else might explain it. ED has many causes (stress, cardiovascular health, other medicines, diabetes, hormonal shifts) and the timing being coincidental is common.

Tell your prescriber what you've noticed and when it started. They can review your full medicines list (some commonly prescribed drugs, including certain blood pressure medicines, are far more closely associated with ED than semaglutide is) and assess whether any dose adjustment or additional investigation makes sense.

You can also report any suspected side effect from a medicine using the MHRA's Yellow Card scheme, that data genuinely helps build the long-term safety picture for newer medicines. If you have broader questions about what Wegovy involves or how treatment is structured, the Wegovy information page is a useful starting point.

We know it can feel awkward raising something like this, most men do not bring it up unless a healthcare professional asks directly. Worth raising it anyway. There are likely straightforward answers.

Does this affect whether semaglutide is suitable for you?

For most men, ED concerns alone would not make semaglutide unsuitable. The eligibility criteria for the medicine centre on BMI, weight-related health conditions, and a clinical review of your individual medical history. A prescriber's job is to look at the whole picture, existing conditions, other medicines you take, and your goals.

You can read more about how the Wegovy 0.25mg starting dose is structured and why the titration schedule is designed the way it is. The detailed page on semaglutide and ED goes further into the pharmacological evidence if you want a more granular look. For context on pricing and what a private prescription includes, the cost and access information lays that out plainly.

If you are thinking about starting treatment, a free consultation with a GPhC-registered prescriber at nume is the right next step. Check your eligibility at the treatment page, consultations are reviewed the same day by a real clinician, not automated software.